ASH 2020 | Effect of daratumumab on MRD measured by NGF in myeloma
Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, discusses the 18-month follow up of the DART4MM study (NCT03992170) evaluating daratumumab efficacy in multiple myeloma patients who achieved a very good partial response (VGPR)/complete response (CR) but remained measurable residual disease (MRD) positive by next-generation flow (NGF) after initial therapy. NGF is a novel high sensitivity approach for myeloma MRD evaluation. Two 8-colour tubes allow the evaluation of all markers needed to differentiate normal from malignant plasma cells (PCs). Long term follow-up investigating the maintenance of MRD negativity will continue. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
